Oncolytics Biotech Inc T.ONC

Here is a quote from Heineman (ONC/Y Chief Medical Officer)

[Proboscises]

"We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy."
 

Might there be more partial responses deepening into complete responses and might the two stable disease patients deepen into partial responses?

This is a new paradigm for pancreatic cancer. No more chemos alone with limited benefit and then relapse. Now pela is allowing the engagement of the patient's own immune system. This opens the possibility of the continuous activity of the immune system against the cancer.  As we see for some the result is a complete response (aka "cure").

[Noteable]

a "cure" is another reason why ONCY's potential M&A valuation could be north of >US$12 Billion, for further reasons already provided.

[inthno]

What I particularly like about this treatment as that it is being used in first line patients if I recall correctly. With this being the case, the patients usually still have a stronger immune system which then also allows for a stronger response to the treatiment IMO....This being said, onc could or should possibly become a first line treatment in a lot of cancer indications rather than being a

[Noteable]

"GOBLET's interim results indicate pelareorep may be the key to finally improving the standard-of-care for first-line treatment of pancreatic cancer, a clear need given that treatment options have not changed for many years despite their limited benefits," commented Thomas C. Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics Biotech Inc. https://www.biospace.com